← Leaderboards
Arnab Chakravarti
Massachusetts General Hospital
$9,324,533
Attributed
$26,487,991
Total exposure
8
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,487,991 · 8
By mechanism
R01$9,239,987 · 4
UG1$7,810,538 · 1
U10$6,842,219 · 1
RC2$2,056,531 · 1
K08$538,716 · 1
Top collaborators
- Claire F Verschraegen9 shared
- David P Carbone7 shared
- William E. Carson7 shared
- David Michael O'Malley7 shared
- Fen Xia6 shared
- Rameen Beroukhim5 shared
- David E Cohn5 shared
- Deliang Guo5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Timothy P Padera$10,637,651
- Harald Paganetti$13,383,713
- Simon N Powell$16,981,652
- Christian Elias Badr$3,737,491
- Henning Willers$1,528,292
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsAdultBaseGlioblastomaMolecularTissuesClinical TrialsPathway InteractionsRadiationIn VivoGrantProteinsPharmacologyTumorGeneticMediatingToxic EffectBiological MarkersGenerationsResourcesResistanceDna DamageEnrollmentUniversities
Grant awards (39)
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,044,921
UG1 · FY2025 · CA
Evolution of gliomas during treatment and resistance$697,603
R01 · FY2025 · CA
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,274,922
UG1 · FY2024 · CA
Evolution of gliomas during treatment and resistance$662,723
R01 · FY2024 · CA
OSU as a Network Lead Academic Participating Site for the NCI NCTN$968,250
UG1 · FY2023 · CA
Evolution of gliomas during treatment and resistance$683,652
R01 · FY2023 · CA
Defining the molecular mechanisms regulating the hexosamine-N-glycosylation pathway in glioblastoma$294,894
R01 · FY2023 · CA
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,083,717
UG1 · FY2022 · CA
Evolution of gliomas during treatment and resistance$683,652
R01 · FY2022 · CA
Defining the molecular mechanisms regulating the hexosamine-N-glycosylation pathway in glioblastoma$292,895
R01 · FY2022 · CA
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,238,889
UG1 · FY2021 · CA
Evolution of gliomas during treatment and resistance$736,601
R01 · FY2021 · CA
Defining the molecular mechanisms regulating the hexosamine-N-glycosylation pathway in glioblastoma$301,456
R01 · FY2021 · CA
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,099,920
UG1 · FY2020 · CA
Defining the molecular mechanisms regulating the hexosamine-N-glycosylation pathway in glioblastoma$306,970
R01 · FY2020 · CA
OSU as a Network Lead Academic Participating Site for the NCI NCTN$1,099,919
UG1 · FY2019 · CA
Defining the molecular mechanisms regulating the hexosamine-N-glycosylation pathway in glioblastoma$312,000
R01 · FY2019 · CA
Novel functions of Pyruvate kinase M2 in DNA double-strand break repair$298,009
R01 · FY2019 · CA
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,311,684
U10 · FY2018 · CA
Novel functions of Pyruvate kinase M2 in DNA double-strand break repair$394,561
R01 · FY2018 · CA
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,307,073
U10 · FY2017 · CA
Novel functions of Pyruvate kinase M2 in DNA double-strand break repair$87,336
R01 · FY2017 · CA
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,384,556
U10 · FY2016 · CA
Novel functions of Pyruvate kinase M2 in DNA double-strand break repair$406,812
R01 · FY2016 · CA
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,383,057
U10 · FY2015 · CA
Novel functions of Pyruvate kinase M2 in DNA double-strand break repair$424,564
R01 · FY2015 · CA
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,455,849
U10 · FY2014 · CA
Novel functions of Pyruvate kinase M2 in DNA double-strand break repair$401,992
R01 · FY2014 · CA
TOWARDS A REFINED MOLECULAR RECURSIVE PARTITIONING ANALYSIS MODEL FOR GLIOBLASTOM$1,020,033
RC2 · FY2010 · CA
TOWARDS A REFINED MOLECULAR RECURSIVE PARTITIONING ANALYSIS MODEL FOR GLIOBLASTOM$1,036,498
RC2 · FY2009 · CA
Signal Transduction Pathways in Glioblastoma$464,424
R01 · FY2009 · CA · contact PI
Signal Transduction Pathways in Glioblastoma$445,200
R01 · FY2008 · CA · contact PI
Signal Transduction Pathways in Glioblastoma$447,893
R01 · FY2007 · CA · contact PI
Signal Transduction Pathways in Glioblastoma$465,277
R01 · FY2006 · CA · contact PI
Signal Transduction Pathways in Glioblastoma$431,473
R01 · FY2005 · CA
INVESTIGATING THE MECHANISMS OF PRB TUMOR SUPPRESSION$134,679
K08 · FY2003 · CA
INVESTIGATING THE MECHANISMS OF PRB TUMOR SUPPRESSION$134,679
K08 · FY2002 · CA
INVESTIGATING THE MECHANISMS OF PRB TUMOR SUPPRESSION$134,679
K08 · FY2001 · CA
INVESTIGATING THE MECHANISMS OF PRB TUMOR SUPPRESSION$134,679
K08 · FY2000 · CA